

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Spearing
Serial No.: 10/597,860 Group Art Unit: 1624
Filed: 10 August 2006 Examiner: Susanna MOORE
For: PTH Agonists

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**REPLY TO REQUIREMENT TO
RESTRICT UNDER 35 U.S.C. § 121**

Sir:

This paper is in response to the Restriction Requirement dated 19 March 2008, setting forth a thirty (30) day shortened statutory period for reply. Applicants herewith request a one (1) month extension of time. Authorization is hereby granted to charge deposit account 19-2570 the amount of \$120.00. Claims 1-6 are pending in the application. Claims 1-6 are subject to restriction and/or election requirement. Please charge any additional fees relating to this paper to Deposit Account No. 19-2570.

Restriction to one of the following invention was required under 35 U.S.C. 121:

- I. Claims 1-5, drawn to thiazolo[3,4-d]pyrimidines and simple compositions thereof.
- II. Claims 1 and 5 drawn to compounds not encompassed by Group (I).
- III. Claim 6, drawn to a method for the preventive and/or therapeutic treatment of osteoporosis.

Applicants hereby elects Group 1 and the specie 3-amino-5-butyl-7-cyclopentylisothiazolo[3,4-*d*]pyrimidine-4,6(5*H*,7*H*)-dione (Example 1).

Applicant reserves the right to prosecute, in one or more patent applications, the canceled claims, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification.

Respectfully submitted,

/JamesMKanagy/

James M. Kanagy
Attorney for Applicants
Registration No. 29,550

GlaxoSmithKline Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5014